Duffy blood antigens are a set of proteins found primarily on the surface of red blood cells (RBCs) that belong to the Duffy blood group system.
These antigens, also known as ACKR1 (Atypical Chemokine Receptor 1) or DARC (Duffy Antigen Receptor for Chemokines), serve critical roles as receptors for both immune signals and certain infectious diseases.
The system consists of five recognized antigens, though two are most commonly tested: Fya and Fyb.
The primary, antithetical antigens produced by codominant alleles (\(FY*A\) and \(FY*B\)).Fy3, Fy5, and Fy6.
Other antigens in the system, with Fy3 being clinically relevant for transfusion reactions.
Duffy-Null Phenotype [Fy(a-b-)]: Characterized by the absence of Fya and Fyb on red blood cells.
It is most common in individuals of West African descent, approaching 100% in some regions.
The Duffy system antigens act as receptors for varied biological agents: Malaria Protection.
The Duffy antigen is the primary entry point for the malaria parasites Plasmodium vivax and Plasmodium knowlesi.
Individuals with the Duffy-null phenotype are largely resistant to these specific types of malaria.
Individuals with the Duffy-null phenotype are largely resistant to these specific types of malaria.
ACKR1 acts as a scavenger or sink for chemokines (immune signaling proteins like IL-8 and RANTES).
ACKR1 helps regulate inflammatory levels by transporting or sequestering these molecules.
Duffy-null individuals often have lower circulating neutrophil counts than standard laboratory reference ranges.
Duffy-null associated neutrophil count (DANC) and does not increase infection risk.
Antibodies to Fya or Fyb (anti-Fya and anti-Fyb) can cause hemolytic transfusion reactions and hemolytic disease of the newborn (HDN).
Anti-Fya is generally more common and more immunogenic than anti-Fyb.
Distribution by Population Population Fya+Fyb+Fy(a-b-) [Null]White/Caucasian~66%~83%RareAsian~99%~18.5%RareBlack/African American~10%~23%~68–100%
The Duffy antigen shows marked geographic and ethnic variation, with distinct allele distributions across different populations worldwide.
Global distribution patterns include the FYA allele being most prevalent globally and particularly common in Asian populations, the FYB allele predominating in European populations, and the FYB^ES^ (Duffy-null) allele found predominantly in sub-Saharan Africa, often reaching fixation across stretches of the continent.
In populations of African descent, the Duffy-negative phenotype Fy(a-b-) is highly prevalent, occurring in 70-95% of individuals.
Among African Americans, approximately 52% are Fy(a-b-), 28% are Fy(a-b+), and 20% are Fy(a+b-).
The FYB^ES^ allele frequency is approximately 78% in African Americans and 88% in Afro-Caribbeans.
In African-Barbadians, 76.5% lack DARC expression on erythrocytes.
European populations predominantly express the Duffy-positive phenotypes, with the FYB allele being most common.
Nearly all Caucasians (approaching 100%) test positive for Duffy antigens.
Asian populations show high frequencies of the FYA allele.
Patients with Duffy null status have lower white cell, and neutrophil counts than those with other genotypes.
Duffy null status is not associated with any clinical conditions, including sepsis, pneumonia, abscesses, or diarrhea.
Duffy null variants are associated with Middle Eastern (14%), Pacific Islander (7%), and Hispanic ancestry of 5%.
Chemokine Regulation: ACKR1 acts as a scavenger for chemokines (immune signaling proteins like IL-8 and RANTES).
It helps regulate inflammatory levels by transporting or sequestering these molecules.
Benign Ethnic Neutropenia (BEN): Duffy-null individuals often have lower circulating neutrophil counts (white blood cells) than standard laboratory reference ranges.
This is a healthy variation known as Duffy-null associated neutrophil count (DANC) and does not increase infection risk.
Antibodies to Fya or Fyb (anti-Fya and anti-Fyb) can cause hemolytic transfusion reactions and hemolytic disease of the newborn (HDN).
Anti-Fya is generally more common and more immunogenic than anti-Fyb.